Pharmaceuticals News

Strategic Combination Brings Highly Innovative Late-Stage D-Fi Franchise Targeting Rare Diseases, with Orphan Drug-Designated Lead Indication in Dystrophic Epidermolysis Bullosa (DEB) Combines Two...

Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation  Satyajit Mitra, Executive Director, Head of...

- Revuforj is the first and only menin inhibitor that is approved for adults and children one year and older with R/R NPM1m AML and KMT2A translocated acute leukemia - NEW YORK, Oct. 30, 2026 ...

KUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced...

Dual vector and AAV.SPR technologies combine to drive supraphysiological levels of full-length MYO7A in non-human primate retina, reaching the macula without foveal detachmentSix-month GLP toxicology...

Biocartis announced that an abstract on its Idylla™ Breast21 Assay has been accepted for poster presentation at the San Antonio Breast Cancer Symposium.

Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML) Fully treated, randomized,...

CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...

"By undertaking these important bioanalytical activities, we are going to obtain great insight into the effects of PPC-001”